Omega-3 / Fish Oil for Hypertension

Verdict: Published with Warning

Across 5 PubMed studies, the evidence for Omega-3 / Fish Oil in Hypertension grades Tier B — preliminary evidence. Effective, but with safety or population caveats.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable

Raw score 0.63

← counter-evidence / ineffectiveeffective / strong evidence →

Final grade

B · Published with Warning

Confidence

87%

Highly consistent evidence

Evidence level

Cochrane high-quality SR/MA

How strongly each layer supports this effect

lower = less supportive

L5 Clinical bodiesAuthoritative stance

0.40

L1 ExamineGlobal benchmark

0.50

L11 AI re-checkIndependent read

0.65

L2 PubMedPrimary literature

0.75

L3 MechanismPlausibility

0.75

Against Mixed Supports

▸View the full decision path (audit trail)

compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.627
tier_from_score — 依分數區間映射至 tier letter
apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
tier_strict_requirement_check — Tier 條件達標，未降階
detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

PMID: 32114706 2020 Cochrane Review n = 162,796

Finding: Increasing long-chain omega-3 (EPA+DHA) had little or no effect on blood pressure (and on mortality/adiposity); the only clear effect was an approximately 15% dose-dependent reduction in triglycerides (high-certainty evidence).

🟢 High quality Government Effect size: Little/no effect on BP; triglycerides reduced ~15% (high-certainty); CHD mortality RR 0.90 (95% CI 0.81-1.00, low-certainty)

View on PubMed

Omega-3 Polyunsaturated Fatty Acids Intake and Blood Pressure: A Dose-Response Meta-Analysis of Randomized Controlled Trials

PMID: 35647665 2022 統合分析 n = 4,973

Finding: At 2-3 g/day EPA+DHA, SBP fell -2.61 mmHg (95% CI -3.57 to -1.65) and DBP -1.64 to -1.80 mmHg (95% CI -2.38 to -0.99), with a J-shaped dose-response and larger effects in hypertensive subgroups.

Academic Effect size: SBP MD -2.61 mmHg (95% CI -3.57,-1.65); DBP MD -1.64 mmHg (95% CI -2.29,-0.99) at 2 g/d

View on PubMed

Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials

PMID: 24610882 2014 統合分析

Finding: Overall EPA+DHA lowered SBP -1.52 mmHg (95% CI -2.25 to -0.79) and DBP -0.99 mmHg (95% CI -1.54 to -0.44); effect was largest in untreated hypertensives (SBP -4.51 mmHg, 95% CI -6.12 to -2.83; DBP -3.05 mmHg, 95% CI -4.35 to -1.74).

⚠️ Industry-funded Effect size: Untreated hypertensives: SBP MD -4.51 mmHg (95% CI -6.12,-2.83); DBP MD -3.05 mmHg (95% CI -4.35,-1.74)

View on PubMed

The beneficial effects of omega-3 polyunsaturated fatty acids on controlling blood pressure: An umbrella meta-analysis

PMID: 36061895 2022 統合分析

Finding: Pooling 10 meta-analyses (20 effect sizes), n-3 PUFA reduced SBP -1.19 mmHg (95% CI -1.76 to -0.62, p<0.001) and DBP -0.91 mmHg (95% CI -1.35 to -0.47, p<0.001), with stronger effects in trials of ≤400 participants and mean age >45.

Academic Effect size: SBP ES -1.19 mmHg (95% CI -1.76,-0.62); DBP ES -0.91 mmHg (95% CI -1.35,-0.47)

View on PubMed

Effects of Omega-3 Fatty Acids Supplementation on Serum Lipid Profile and Blood Pressure in Patients with Metabolic Syndrome: A Systematic Review and Meta-Analysis of RCTs

PMID: 36832799 2023 統合分析 n = 387

Finding: In metabolic syndrome patients, omega-3 significantly reduced SBP (SMD -0.54, 95% CI -0.86 to -0.22) and DBP (SMD -0.56, 95% CI -0.79 to -0.33), but the evidence base is small (8 RCTs, 387 participants).

🟠 Limited quality Government Effect size: SBP SMD -0.54 (95% CI -0.86,-0.22); DBP SMD -0.56 (95% CI -0.79,-0.33)

View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA

Supportive

Generally Recognized As Safe (GRAS) - authorized under 21 CFR 184.1472 source↗

L4b EU EFSA

Supportive

intakes of 250mg a day sufficient for normal cardiac function source↗

L4c UK NHS

Neutral

at least 2 portions of fish a week, including 1 of oily fish source↗

L4d TW TFDA / 衛福部

Supportive

每日攝取量所含之ω-3脂肪酸至少應達一．○克 source↗

L4e WHO

Neutral

2 g/day of purified omega-3 fatty acids offer substantial advantages source↗

L5a NIH Office of Dietary Supplements

Supportive

ALA is an essential fatty acid source↗

L5b Mayo Clinic

Cautious

Multiple studies report modest reductions in blood pressure in people who take fish oil supplements. There's some evidence that the beneficial effects of fish oil might be greater for people with moderate to severe high blood pressure than for those with mild blood pressure elevation. Some studies have shown that taking a fish oil supplement (4 grams daily) modestly reduces blood pressure in pa… source↗

L5c Cleveland Clinic

Cautious

Omega-3s may help you by raising your HDL (good) cholesterol and lowering your blood pressure. source↗

L5d Harvard Health

Cautious

Omega-3s benefit the heart and blood vessels by reducing triglycerides, lowering the risk of arrhythmias, slowing plaque buildup in arteries, and slightly lowering blood pressure. Omega-3 fatty acids have real cardiovascular benefits, in part because they lower heart rate and blood pressure, and improve the health of blood vessels. source↗

L5e Specialty Society (condition-mapped)

Cautious

About 3 grams daily of omega-3 fatty acids, consumed in foods or supplements, appears to be the optimal daily dose to help lower blood pressure. source↗

✓PMID 100% verifiedevery citation checked via NCBI Entrez

🔬5 PubMed studiesindependently re-checked by multiple sub-agents

engine_version: v1.0 claim_id: CLM-COND-hypertension-INT-omega-3-fatty-acids-001 繁體中文版 →